SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-123915
Filing Date
2020-11-12
Accepted
2020-11-12 07:00:25
Documents
12
Period of Report
2020-11-10
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2035694d1_8k.htm   iXBRL 8-K 37543
  Complete submission text file 0001104659-20-123915.txt   212793

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bcli-20201110.xsd EX-101.SCH 3207
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20201110_lab.xml EX-101.LAB 34591
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20201110_pre.xml EX-101.PRE 22724
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2035694d1_8k_htm.xml XML 3617
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 201303263
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences